Global Pain Management Therapeutics Market

Pain Management Therapeutics Comprehensive Study by Type (Antidepressants, Anesthetics, NSAIDs, Opioids, Anti-Migraine Agents, Other), Application (Burn Pain, Cancer Pain, Dental/Facial Pain, Migraine Headache Pain, Musculoskeletal Pain, Neuropathic Pain, Obstetrical Pain, Others), Indication (Neuropathic Pain, Arthritic Pain, Cancer pain, Post-operative Pain, Chronic Back Pain, Fibromyalgia, A migraine), Drug Class (Anesthetics, NSAIDS, Anticonvulsants, Antidepressants, Anti-migraine agents, Non-narcotic analgesics, Opioids), Distribution channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Europe Market Outlook to 2030

Pain Management Therapeutics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 3.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Pain Management Therapeutics Market Scope
According to the estimation of the National Health Interview Survey (NHIS), about 25.3 million adults, i.e.11.2% of adults suffered from pain every day and 12.7% experience chronic pain. The global market for pain management therapeutics is expected to increase in the coming years due to improving healthcare infrastructure, Increasing economic stability and increased penetration of players in emerging economies. One among that severe pain inducing disease is ‘Cancer pain’. World Health Organization has projected that “Global cancer prevalence will increase by almost 75% from 2008 to 2030”. The increasing rate of cancer cases worldwide will further contribute to the rise in demand for pain management therapeutics thereby driving this market. Pain is an unpleasant sensation and emotional experience linked to tissue damage. Pain management involves the process of treating all types of pain (Acute and Chronic), including musculoskeletal, spinal and neuropathic pain disorders. With an accurate diagnosis and early intervention, pain management therapeutics helps patients to avoid the state of chronic pain, or at least reduce the severity of pain. Pain management can be most effective only when the underlying disease conditions are cured. Minimally invasive procedures and proper use of medications are implemented to achieve pain management goals among individuals.

According to AMA, the Europe Pain Management Therapeutics market is expected to see growth rate of 3.5%

The market is fragmented by both small and big players who have locked horns with each other in the market and are making tireless efforts to gain supremacy over their counterparts. This cut-throat competition is expected to prove beneficial for the consumers who will now have a wide range of vendors, each of whom is willing to go an extra mile to attract the consumers. The strategy that can help these players in growing their customer base and expansion of their product portfolio. Research Analyst at AMA estimates that United Kingdom Players will contribute to the maximum growth of Europe Pain Management Therapeutics market throughout the predicted period.

Pfizer Inc. (United States), Endo International Plc. (Ireland), Depomed, Inc. (United States), Purdue Pharma L.P. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Mallinckrodt Pharmaceuticals (UK), AstraZeneca PLC. (UK), Novartis AG(Switzerland), Merck & Co. Inc. (United States) and Johnson & Johnson Services, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are GlaxoSmithKline Plc (UK) and Abbott Laboratories (United States).

Segmentation Overview
The study have segmented the market of Europe Pain Management Therapeutics market by Type (Antidepressants, Anesthetics, NSAIDs, Opioids, Anti-Migraine Agents and Other), by Application (Burn Pain, Cancer Pain, Dental/Facial Pain, Migraine Headache Pain, Musculoskeletal Pain, Neuropathic Pain, Obstetrical Pain and Others) and Region with country level break-up.

On the basis of geography, the market of Pain Management Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Influencing Trend:
The increasing prevalence of several pain- inducing diseases leading to the growth of counteractive treatment thereby using pain management therapeutics devices and Consumption of over-the-counter (OTC) drugs rather than prescription drugs among patients.

Market Growth Drivers:
The increasing number of patients suffering from chronic pain, Increasing incidence of Cancer worldwide, Improving healthcare reforms and regulatory aspects and Increase in geriatric population with high risk of diseases.

Challenges:
Low diagnosis and prescription rates for pain management among patients, The expected expiry of blockbuster pain management drugs., Pain management R&D including unmet needs, Clinical trial design and alternative R&D approaches, Potential pain biomarkers, Functional imaging techniques and Pain considerably affects day-to-day activities in life and its management is a considerable challenge for the physicians.

Restraints:
Alternative therapies and surgical procedures during pain relief from medical devices, Prescription drug exploitation and lack of skilled or trained physicians and The absence of perfect pain management solution.

Opportunities:
Improving healthcare infrastructure, increasing economic stability and increases penetration of players emerging economies.

Market Leaders and their Expansionary Development Strategies
In May , 2021 Heron Therapeutics, Inc. a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.
In January 2021,Abbott announced the upcoming launch of NeuroSphere myPath, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy.


Key Target Audience
Hospitals, Health Care providers, Medical practitioners, Traders, Distributors, Suppliers, Pain Management Therapeutics Manufacturers and Government and regional agencies

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Antidepressants
  • Anesthetics
  • NSAIDs
  • Opioids
  • Anti-Migraine Agents
  • Other
By Application
  • Burn Pain
  • Cancer Pain
  • Dental/Facial Pain
  • Migraine Headache Pain
  • Musculoskeletal Pain
  • Neuropathic Pain
  • Obstetrical Pain
  • Others
By Indication
  • Neuropathic Pain
  • Arthritic Pain
  • Cancer pain
  • Post-operative Pain
  • Chronic Back Pain
  • Fibromyalgia
  • A migraine

By Drug Class
  • Anesthetics
  • NSAIDS
  • Anticonvulsants
  • Antidepressants
  • Anti-migraine agents
  • Non-narcotic analgesics
  • Opioids

By Distribution channel
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing number of patients suffering from chronic pain
      • 3.2.2. Increasing incidence of Cancer worldwide
      • 3.2.3. Improving healthcare reforms and regulatory aspects
      • 3.2.4. Increase in geriatric population with high risk of diseases.
    • 3.3. Market Challenges
      • 3.3.1. Low diagnosis and prescription rates for pain management among patients
      • 3.3.2. The expected expiry of blockbuster pain management drugs.
      • 3.3.3. Pain management R&D including unmet needs
      • 3.3.4. Clinical trial design and alternative R&D approaches
      • 3.3.5. Potential pain biomarkers
      • 3.3.6. Functional imaging techniques
      • 3.3.7. Pain considerably affects day-to-day activities in life and its management is a considerable challenge for the physicians.
    • 3.4. Market Trends
      • 3.4.1. The increasing prevalence of several pain- inducing diseases leading to the growth of counteractive treatment thereby using pain management therapeutics devices
      • 3.4.2. Consumption of over-the-counter (OTC) drugs rather than prescription drugs among patients.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Europe Pain Management Therapeutics, by Type, Application, Indication , Drug Class, Distribution channel and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Europe Pain Management Therapeutics (Value)
      • 5.2.1. Europe Pain Management Therapeutics by: Type (Value)
        • 5.2.1.1. Antidepressants
        • 5.2.1.2. Anesthetics
        • 5.2.1.3. NSAIDs
        • 5.2.1.4. Opioids
        • 5.2.1.5. Anti-Migraine Agents
        • 5.2.1.6. Other
      • 5.2.2. Europe Pain Management Therapeutics by: Application (Value)
        • 5.2.2.1. Burn Pain
        • 5.2.2.2. Cancer Pain
        • 5.2.2.3. Dental/Facial Pain
        • 5.2.2.4. Migraine Headache Pain
        • 5.2.2.5. Musculoskeletal Pain
        • 5.2.2.6. Neuropathic Pain
        • 5.2.2.7. Obstetrical Pain
        • 5.2.2.8. Others
      • 5.2.3. Europe Pain Management Therapeutics by: Drug Class (Value)
        • 5.2.3.1. Anesthetics
        • 5.2.3.2. NSAIDS
        • 5.2.3.3. Anticonvulsants
        • 5.2.3.4. Antidepressants
        • 5.2.3.5. Anti-migraine agents
        • 5.2.3.6. Non-narcotic analgesics
        • 5.2.3.7. Opioids
      • 5.2.4. Europe Pain Management Therapeutics by: Distribution channel (Value)
        • 5.2.4.1. Hospitals Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
      • 5.2.5. Europe Pain Management Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Europe Pain Management Therapeutics (Volume)
      • 5.3.1. Europe Pain Management Therapeutics by: Type (Volume)
        • 5.3.1.1. Antidepressants
        • 5.3.1.2. Anesthetics
        • 5.3.1.3. NSAIDs
        • 5.3.1.4. Opioids
        • 5.3.1.5. Anti-Migraine Agents
        • 5.3.1.6. Other
      • 5.3.2. Europe Pain Management Therapeutics by: Application (Volume)
        • 5.3.2.1. Burn Pain
        • 5.3.2.2. Cancer Pain
        • 5.3.2.3. Dental/Facial Pain
        • 5.3.2.4. Migraine Headache Pain
        • 5.3.2.5. Musculoskeletal Pain
        • 5.3.2.6. Neuropathic Pain
        • 5.3.2.7. Obstetrical Pain
        • 5.3.2.8. Others
      • 5.3.3. Europe Pain Management Therapeutics by: Drug Class (Volume)
        • 5.3.3.1. Anesthetics
        • 5.3.3.2. NSAIDS
        • 5.3.3.3. Anticonvulsants
        • 5.3.3.4. Antidepressants
        • 5.3.3.5. Anti-migraine agents
        • 5.3.3.6. Non-narcotic analgesics
        • 5.3.3.7. Opioids
      • 5.3.4. Europe Pain Management Therapeutics by: Distribution channel (Volume)
        • 5.3.4.1. Hospitals Pharmacy
        • 5.3.4.2. Retail Pharmacy
        • 5.3.4.3. Online Pharmacy
      • 5.3.5. Europe Pain Management Therapeutics Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Europe Pain Management Therapeutics (Price)
      • 5.4.1. Europe Pain Management Therapeutics by: Type (Price)
  • 6. Pain Management Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Endo International Plc. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Depomed, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Purdue Pharma L.P. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mallinckrodt Pharmaceuticals (UK)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca PLC. (UK)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG(Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co. Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson Services, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Europe Pain Management Therapeutics Sale, by Type, Application, Indication , Drug Class, Distribution channel and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Europe Pain Management Therapeutics (Value)
      • 7.2.1. Europe Pain Management Therapeutics by: Type (Value)
        • 7.2.1.1. Antidepressants
        • 7.2.1.2. Anesthetics
        • 7.2.1.3. NSAIDs
        • 7.2.1.4. Opioids
        • 7.2.1.5. Anti-Migraine Agents
        • 7.2.1.6. Other
      • 7.2.2. Europe Pain Management Therapeutics by: Application (Value)
        • 7.2.2.1. Burn Pain
        • 7.2.2.2. Cancer Pain
        • 7.2.2.3. Dental/Facial Pain
        • 7.2.2.4. Migraine Headache Pain
        • 7.2.2.5. Musculoskeletal Pain
        • 7.2.2.6. Neuropathic Pain
        • 7.2.2.7. Obstetrical Pain
        • 7.2.2.8. Others
      • 7.2.3. Europe Pain Management Therapeutics by: Drug Class (Value)
        • 7.2.3.1. Anesthetics
        • 7.2.3.2. NSAIDS
        • 7.2.3.3. Anticonvulsants
        • 7.2.3.4. Antidepressants
        • 7.2.3.5. Anti-migraine agents
        • 7.2.3.6. Non-narcotic analgesics
        • 7.2.3.7. Opioids
      • 7.2.4. Europe Pain Management Therapeutics by: Distribution channel (Value)
        • 7.2.4.1. Hospitals Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
      • 7.2.5. Europe Pain Management Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Europe Pain Management Therapeutics (Volume)
      • 7.3.1. Europe Pain Management Therapeutics by: Type (Volume)
        • 7.3.1.1. Antidepressants
        • 7.3.1.2. Anesthetics
        • 7.3.1.3. NSAIDs
        • 7.3.1.4. Opioids
        • 7.3.1.5. Anti-Migraine Agents
        • 7.3.1.6. Other
      • 7.3.2. Europe Pain Management Therapeutics by: Application (Volume)
        • 7.3.2.1. Burn Pain
        • 7.3.2.2. Cancer Pain
        • 7.3.2.3. Dental/Facial Pain
        • 7.3.2.4. Migraine Headache Pain
        • 7.3.2.5. Musculoskeletal Pain
        • 7.3.2.6. Neuropathic Pain
        • 7.3.2.7. Obstetrical Pain
        • 7.3.2.8. Others
      • 7.3.3. Europe Pain Management Therapeutics by: Drug Class (Volume)
        • 7.3.3.1. Anesthetics
        • 7.3.3.2. NSAIDS
        • 7.3.3.3. Anticonvulsants
        • 7.3.3.4. Antidepressants
        • 7.3.3.5. Anti-migraine agents
        • 7.3.3.6. Non-narcotic analgesics
        • 7.3.3.7. Opioids
      • 7.3.4. Europe Pain Management Therapeutics by: Distribution channel (Volume)
        • 7.3.4.1. Hospitals Pharmacy
        • 7.3.4.2. Retail Pharmacy
        • 7.3.4.3. Online Pharmacy
      • 7.3.5. Europe Pain Management Therapeutics Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Europe Pain Management Therapeutics (Price)
      • 7.4.1. Europe Pain Management Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pain Management Therapeutics: by Type(USD Million)
  • Table 2. Pain Management Therapeutics Antidepressants , by Region USD Million (2018-2023)
  • Table 3. Pain Management Therapeutics Anesthetics , by Region USD Million (2018-2023)
  • Table 4. Pain Management Therapeutics NSAIDs , by Region USD Million (2018-2023)
  • Table 5. Pain Management Therapeutics Opioids , by Region USD Million (2018-2023)
  • Table 6. Pain Management Therapeutics Anti-Migraine Agents , by Region USD Million (2018-2023)
  • Table 7. Pain Management Therapeutics Other , by Region USD Million (2018-2023)
  • Table 8. Pain Management Therapeutics: by Application(USD Million)
  • Table 9. Pain Management Therapeutics Burn Pain , by Region USD Million (2018-2023)
  • Table 10. Pain Management Therapeutics Cancer Pain , by Region USD Million (2018-2023)
  • Table 11. Pain Management Therapeutics Dental/Facial Pain , by Region USD Million (2018-2023)
  • Table 12. Pain Management Therapeutics Migraine Headache Pain , by Region USD Million (2018-2023)
  • Table 13. Pain Management Therapeutics Musculoskeletal Pain , by Region USD Million (2018-2023)
  • Table 14. Pain Management Therapeutics Neuropathic Pain , by Region USD Million (2018-2023)
  • Table 15. Pain Management Therapeutics Obstetrical Pain , by Region USD Million (2018-2023)
  • Table 16. Pain Management Therapeutics Others , by Region USD Million (2018-2023)
  • Table 17. Pain Management Therapeutics: by Drug Class(USD Million)
  • Table 18. Pain Management Therapeutics Anesthetics , by Region USD Million (2018-2023)
  • Table 19. Pain Management Therapeutics NSAIDS , by Region USD Million (2018-2023)
  • Table 20. Pain Management Therapeutics Anticonvulsants , by Region USD Million (2018-2023)
  • Table 21. Pain Management Therapeutics Antidepressants , by Region USD Million (2018-2023)
  • Table 22. Pain Management Therapeutics Anti-migraine agents , by Region USD Million (2018-2023)
  • Table 23. Pain Management Therapeutics Non-narcotic analgesics , by Region USD Million (2018-2023)
  • Table 24. Pain Management Therapeutics Opioids , by Region USD Million (2018-2023)
  • Table 25. Pain Management Therapeutics: by Distribution channel(USD Million)
  • Table 26. Pain Management Therapeutics Hospitals Pharmacy , by Region USD Million (2018-2023)
  • Table 27. Pain Management Therapeutics Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 28. Pain Management Therapeutics Online Pharmacy , by Region USD Million (2018-2023)
  • Table 29. South America Pain Management Therapeutics, by Country USD Million (2018-2023)
  • Table 30. South America Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 31. South America Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 32. South America Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 33. South America Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 34. South America Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 35. Brazil Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 36. Brazil Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 37. Brazil Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 38. Brazil Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 39. Brazil Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 40. Argentina Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 41. Argentina Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 42. Argentina Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 43. Argentina Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 44. Argentina Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 45. Rest of South America Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 46. Rest of South America Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 47. Rest of South America Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 48. Rest of South America Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 49. Rest of South America Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 50. Asia Pacific Pain Management Therapeutics, by Country USD Million (2018-2023)
  • Table 51. Asia Pacific Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 52. Asia Pacific Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 53. Asia Pacific Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 54. Asia Pacific Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 55. Asia Pacific Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 56. China Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 57. China Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 58. China Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 59. China Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 60. China Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 61. Japan Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 62. Japan Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 63. Japan Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 64. Japan Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 65. Japan Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 66. India Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 67. India Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 68. India Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 69. India Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 70. India Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 71. South Korea Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 72. South Korea Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 73. South Korea Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 74. South Korea Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 75. South Korea Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 76. Taiwan Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 77. Taiwan Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 78. Taiwan Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 79. Taiwan Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 80. Taiwan Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 81. Australia Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 82. Australia Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 83. Australia Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 84. Australia Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 85. Australia Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 90. Rest of Asia-Pacific Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 91. Europe Pain Management Therapeutics, by Country USD Million (2018-2023)
  • Table 92. Europe Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 93. Europe Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 94. Europe Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 95. Europe Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 96. Europe Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 97. Germany Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 98. Germany Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 99. Germany Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 100. Germany Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 101. Germany Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 102. France Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 103. France Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 104. France Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 105. France Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 106. France Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 107. Italy Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 108. Italy Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 109. Italy Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 110. Italy Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 111. Italy Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 112. United Kingdom Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 113. United Kingdom Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 114. United Kingdom Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 115. United Kingdom Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 116. United Kingdom Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 117. Netherlands Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 118. Netherlands Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 119. Netherlands Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 120. Netherlands Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 121. Netherlands Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 122. Rest of Europe Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 123. Rest of Europe Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 124. Rest of Europe Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 125. Rest of Europe Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 126. Rest of Europe Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 127. MEA Pain Management Therapeutics, by Country USD Million (2018-2023)
  • Table 128. MEA Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 129. MEA Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 130. MEA Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 131. MEA Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 132. MEA Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 133. Middle East Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 134. Middle East Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 135. Middle East Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 136. Middle East Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 137. Middle East Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 138. Africa Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 139. Africa Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 140. Africa Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 141. Africa Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 142. Africa Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 143. North America Pain Management Therapeutics, by Country USD Million (2018-2023)
  • Table 144. North America Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 145. North America Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 146. North America Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 147. North America Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 148. North America Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 149. United States Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 150. United States Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 151. United States Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 152. United States Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 153. United States Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 154. Canada Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 155. Canada Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 156. Canada Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 157. Canada Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 158. Canada Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 159. Mexico Pain Management Therapeutics, by Type USD Million (2018-2023)
  • Table 160. Mexico Pain Management Therapeutics, by Application USD Million (2018-2023)
  • Table 161. Mexico Pain Management Therapeutics, by Indication USD Million (2018-2023)
  • Table 162. Mexico Pain Management Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 163. Mexico Pain Management Therapeutics, by Distribution channel USD Million (2018-2023)
  • Table 164. Pain Management Therapeutics Sales: by Type(K Units)
  • Table 165. Pain Management Therapeutics Sales Antidepressants , by Region K Units (2018-2023)
  • Table 166. Pain Management Therapeutics Sales Anesthetics , by Region K Units (2018-2023)
  • Table 167. Pain Management Therapeutics Sales NSAIDs , by Region K Units (2018-2023)
  • Table 168. Pain Management Therapeutics Sales Opioids , by Region K Units (2018-2023)
  • Table 169. Pain Management Therapeutics Sales Anti-Migraine Agents , by Region K Units (2018-2023)
  • Table 170. Pain Management Therapeutics Sales Other , by Region K Units (2018-2023)
  • Table 171. Pain Management Therapeutics Sales: by Application(K Units)
  • Table 172. Pain Management Therapeutics Sales Burn Pain , by Region K Units (2018-2023)
  • Table 173. Pain Management Therapeutics Sales Cancer Pain , by Region K Units (2018-2023)
  • Table 174. Pain Management Therapeutics Sales Dental/Facial Pain , by Region K Units (2018-2023)
  • Table 175. Pain Management Therapeutics Sales Migraine Headache Pain , by Region K Units (2018-2023)
  • Table 176. Pain Management Therapeutics Sales Musculoskeletal Pain , by Region K Units (2018-2023)
  • Table 177. Pain Management Therapeutics Sales Neuropathic Pain , by Region K Units (2018-2023)
  • Table 178. Pain Management Therapeutics Sales Obstetrical Pain , by Region K Units (2018-2023)
  • Table 179. Pain Management Therapeutics Sales Others , by Region K Units (2018-2023)
  • Table 180. Pain Management Therapeutics Sales: by Drug Class(K Units)
  • Table 181. Pain Management Therapeutics Sales Anesthetics , by Region K Units (2018-2023)
  • Table 182. Pain Management Therapeutics Sales NSAIDS , by Region K Units (2018-2023)
  • Table 183. Pain Management Therapeutics Sales Anticonvulsants , by Region K Units (2018-2023)
  • Table 184. Pain Management Therapeutics Sales Antidepressants , by Region K Units (2018-2023)
  • Table 185. Pain Management Therapeutics Sales Anti-migraine agents , by Region K Units (2018-2023)
  • Table 186. Pain Management Therapeutics Sales Non-narcotic analgesics , by Region K Units (2018-2023)
  • Table 187. Pain Management Therapeutics Sales Opioids , by Region K Units (2018-2023)
  • Table 188. Pain Management Therapeutics Sales: by Distribution channel(K Units)
  • Table 189. Pain Management Therapeutics Sales Hospitals Pharmacy , by Region K Units (2018-2023)
  • Table 190. Pain Management Therapeutics Sales Retail Pharmacy , by Region K Units (2018-2023)
  • Table 191. Pain Management Therapeutics Sales Online Pharmacy , by Region K Units (2018-2023)
  • Table 192. South America Pain Management Therapeutics Sales, by Country K Units (2018-2023)
  • Table 193. South America Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 194. South America Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 195. South America Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 196. South America Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 197. South America Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 198. Brazil Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 199. Brazil Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 200. Brazil Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 201. Brazil Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 202. Brazil Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 203. Argentina Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 204. Argentina Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 205. Argentina Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 206. Argentina Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 207. Argentina Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 208. Rest of South America Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 209. Rest of South America Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 210. Rest of South America Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 211. Rest of South America Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 212. Rest of South America Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 213. Asia Pacific Pain Management Therapeutics Sales, by Country K Units (2018-2023)
  • Table 214. Asia Pacific Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 215. Asia Pacific Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 216. Asia Pacific Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 217. Asia Pacific Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 218. Asia Pacific Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 219. China Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 220. China Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 221. China Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 222. China Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 223. China Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 224. Japan Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 225. Japan Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 226. Japan Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 227. Japan Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 228. Japan Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 229. India Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 230. India Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 231. India Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 232. India Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 233. India Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 234. South Korea Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 235. South Korea Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 236. South Korea Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 237. South Korea Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 238. South Korea Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 239. Taiwan Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 240. Taiwan Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 241. Taiwan Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 242. Taiwan Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 243. Taiwan Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 244. Australia Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 245. Australia Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 246. Australia Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 247. Australia Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 248. Australia Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 249. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 250. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 251. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 252. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 253. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 254. Europe Pain Management Therapeutics Sales, by Country K Units (2018-2023)
  • Table 255. Europe Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 256. Europe Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 257. Europe Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 258. Europe Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 259. Europe Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 260. Germany Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 261. Germany Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 262. Germany Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 263. Germany Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 264. Germany Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 265. France Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 266. France Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 267. France Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 268. France Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 269. France Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 270. Italy Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 271. Italy Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 272. Italy Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 273. Italy Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 274. Italy Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 275. United Kingdom Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 276. United Kingdom Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 277. United Kingdom Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 278. United Kingdom Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 279. United Kingdom Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 280. Netherlands Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 281. Netherlands Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 282. Netherlands Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 283. Netherlands Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 284. Netherlands Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 285. Rest of Europe Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 286. Rest of Europe Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 287. Rest of Europe Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 288. Rest of Europe Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 289. Rest of Europe Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 290. MEA Pain Management Therapeutics Sales, by Country K Units (2018-2023)
  • Table 291. MEA Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 292. MEA Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 293. MEA Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 294. MEA Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 295. MEA Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 296. Middle East Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 297. Middle East Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 298. Middle East Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 299. Middle East Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 300. Middle East Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 301. Africa Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 302. Africa Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 303. Africa Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 304. Africa Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 305. Africa Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 306. North America Pain Management Therapeutics Sales, by Country K Units (2018-2023)
  • Table 307. North America Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 308. North America Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 309. North America Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 310. North America Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 311. North America Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 312. United States Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 313. United States Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 314. United States Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 315. United States Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 316. United States Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 317. Canada Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 318. Canada Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 319. Canada Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 320. Canada Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 321. Canada Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 322. Mexico Pain Management Therapeutics Sales, by Type K Units (2018-2023)
  • Table 323. Mexico Pain Management Therapeutics Sales, by Application K Units (2018-2023)
  • Table 324. Mexico Pain Management Therapeutics Sales, by Indication K Units (2018-2023)
  • Table 325. Mexico Pain Management Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 326. Mexico Pain Management Therapeutics Sales, by Distribution channel K Units (2018-2023)
  • Table 327. Pain Management Therapeutics: by Type(USD/Units)
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Company Basic Information, Sales Area and Its Competitors
  • Table 337. Company Basic Information, Sales Area and Its Competitors
  • Table 338. Pain Management Therapeutics: by Type(USD Million)
  • Table 339. Pain Management Therapeutics Antidepressants , by Region USD Million (2025-2030)
  • Table 340. Pain Management Therapeutics Anesthetics , by Region USD Million (2025-2030)
  • Table 341. Pain Management Therapeutics NSAIDs , by Region USD Million (2025-2030)
  • Table 342. Pain Management Therapeutics Opioids , by Region USD Million (2025-2030)
  • Table 343. Pain Management Therapeutics Anti-Migraine Agents , by Region USD Million (2025-2030)
  • Table 344. Pain Management Therapeutics Other , by Region USD Million (2025-2030)
  • Table 345. Pain Management Therapeutics: by Application(USD Million)
  • Table 346. Pain Management Therapeutics Burn Pain , by Region USD Million (2025-2030)
  • Table 347. Pain Management Therapeutics Cancer Pain , by Region USD Million (2025-2030)
  • Table 348. Pain Management Therapeutics Dental/Facial Pain , by Region USD Million (2025-2030)
  • Table 349. Pain Management Therapeutics Migraine Headache Pain , by Region USD Million (2025-2030)
  • Table 350. Pain Management Therapeutics Musculoskeletal Pain , by Region USD Million (2025-2030)
  • Table 351. Pain Management Therapeutics Neuropathic Pain , by Region USD Million (2025-2030)
  • Table 352. Pain Management Therapeutics Obstetrical Pain , by Region USD Million (2025-2030)
  • Table 353. Pain Management Therapeutics Others , by Region USD Million (2025-2030)
  • Table 354. Pain Management Therapeutics: by Drug Class(USD Million)
  • Table 355. Pain Management Therapeutics Anesthetics , by Region USD Million (2025-2030)
  • Table 356. Pain Management Therapeutics NSAIDS , by Region USD Million (2025-2030)
  • Table 357. Pain Management Therapeutics Anticonvulsants , by Region USD Million (2025-2030)
  • Table 358. Pain Management Therapeutics Antidepressants , by Region USD Million (2025-2030)
  • Table 359. Pain Management Therapeutics Anti-migraine agents , by Region USD Million (2025-2030)
  • Table 360. Pain Management Therapeutics Non-narcotic analgesics , by Region USD Million (2025-2030)
  • Table 361. Pain Management Therapeutics Opioids , by Region USD Million (2025-2030)
  • Table 362. Pain Management Therapeutics: by Distribution channel(USD Million)
  • Table 363. Pain Management Therapeutics Hospitals Pharmacy , by Region USD Million (2025-2030)
  • Table 364. Pain Management Therapeutics Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 365. Pain Management Therapeutics Online Pharmacy , by Region USD Million (2025-2030)
  • Table 366. South America Pain Management Therapeutics, by Country USD Million (2025-2030)
  • Table 367. South America Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 368. South America Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 369. South America Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 370. South America Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 371. South America Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 372. Brazil Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 373. Brazil Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 374. Brazil Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 375. Brazil Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 376. Brazil Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 377. Argentina Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 378. Argentina Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 379. Argentina Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 380. Argentina Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 381. Argentina Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 382. Rest of South America Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 383. Rest of South America Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 384. Rest of South America Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 385. Rest of South America Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 386. Rest of South America Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 387. Asia Pacific Pain Management Therapeutics, by Country USD Million (2025-2030)
  • Table 388. Asia Pacific Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 389. Asia Pacific Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 390. Asia Pacific Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 391. Asia Pacific Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 392. Asia Pacific Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 393. China Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 394. China Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 395. China Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 396. China Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 397. China Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 398. Japan Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 399. Japan Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 400. Japan Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 401. Japan Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 402. Japan Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 403. India Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 404. India Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 405. India Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 406. India Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 407. India Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 408. South Korea Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 409. South Korea Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 410. South Korea Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 411. South Korea Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 412. South Korea Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 413. Taiwan Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 414. Taiwan Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 415. Taiwan Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 416. Taiwan Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 417. Taiwan Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 418. Australia Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 419. Australia Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 420. Australia Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 421. Australia Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 422. Australia Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 423. Rest of Asia-Pacific Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 424. Rest of Asia-Pacific Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 425. Rest of Asia-Pacific Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 426. Rest of Asia-Pacific Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 427. Rest of Asia-Pacific Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 428. Europe Pain Management Therapeutics, by Country USD Million (2025-2030)
  • Table 429. Europe Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 430. Europe Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 431. Europe Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 432. Europe Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 433. Europe Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 434. Germany Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 435. Germany Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 436. Germany Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 437. Germany Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 438. Germany Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 439. France Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 440. France Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 441. France Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 442. France Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 443. France Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 444. Italy Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 445. Italy Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 446. Italy Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 447. Italy Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 448. Italy Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 449. United Kingdom Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 450. United Kingdom Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 451. United Kingdom Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 452. United Kingdom Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 453. United Kingdom Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 454. Netherlands Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 455. Netherlands Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 456. Netherlands Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 457. Netherlands Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 458. Netherlands Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 459. Rest of Europe Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 460. Rest of Europe Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 461. Rest of Europe Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 462. Rest of Europe Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 463. Rest of Europe Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 464. MEA Pain Management Therapeutics, by Country USD Million (2025-2030)
  • Table 465. MEA Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 466. MEA Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 467. MEA Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 468. MEA Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 469. MEA Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 470. Middle East Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 471. Middle East Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 472. Middle East Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 473. Middle East Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 474. Middle East Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 475. Africa Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 476. Africa Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 477. Africa Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 478. Africa Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 479. Africa Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 480. North America Pain Management Therapeutics, by Country USD Million (2025-2030)
  • Table 481. North America Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 482. North America Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 483. North America Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 484. North America Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 485. North America Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 486. United States Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 487. United States Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 488. United States Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 489. United States Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 490. United States Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 491. Canada Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 492. Canada Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 493. Canada Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 494. Canada Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 495. Canada Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 496. Mexico Pain Management Therapeutics, by Type USD Million (2025-2030)
  • Table 497. Mexico Pain Management Therapeutics, by Application USD Million (2025-2030)
  • Table 498. Mexico Pain Management Therapeutics, by Indication USD Million (2025-2030)
  • Table 499. Mexico Pain Management Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 500. Mexico Pain Management Therapeutics, by Distribution channel USD Million (2025-2030)
  • Table 501. Pain Management Therapeutics Sales: by Type(K Units)
  • Table 502. Pain Management Therapeutics Sales Antidepressants , by Region K Units (2025-2030)
  • Table 503. Pain Management Therapeutics Sales Anesthetics , by Region K Units (2025-2030)
  • Table 504. Pain Management Therapeutics Sales NSAIDs , by Region K Units (2025-2030)
  • Table 505. Pain Management Therapeutics Sales Opioids , by Region K Units (2025-2030)
  • Table 506. Pain Management Therapeutics Sales Anti-Migraine Agents , by Region K Units (2025-2030)
  • Table 507. Pain Management Therapeutics Sales Other , by Region K Units (2025-2030)
  • Table 508. Pain Management Therapeutics Sales: by Application(K Units)
  • Table 509. Pain Management Therapeutics Sales Burn Pain , by Region K Units (2025-2030)
  • Table 510. Pain Management Therapeutics Sales Cancer Pain , by Region K Units (2025-2030)
  • Table 511. Pain Management Therapeutics Sales Dental/Facial Pain , by Region K Units (2025-2030)
  • Table 512. Pain Management Therapeutics Sales Migraine Headache Pain , by Region K Units (2025-2030)
  • Table 513. Pain Management Therapeutics Sales Musculoskeletal Pain , by Region K Units (2025-2030)
  • Table 514. Pain Management Therapeutics Sales Neuropathic Pain , by Region K Units (2025-2030)
  • Table 515. Pain Management Therapeutics Sales Obstetrical Pain , by Region K Units (2025-2030)
  • Table 516. Pain Management Therapeutics Sales Others , by Region K Units (2025-2030)
  • Table 517. Pain Management Therapeutics Sales: by Drug Class(K Units)
  • Table 518. Pain Management Therapeutics Sales Anesthetics , by Region K Units (2025-2030)
  • Table 519. Pain Management Therapeutics Sales NSAIDS , by Region K Units (2025-2030)
  • Table 520. Pain Management Therapeutics Sales Anticonvulsants , by Region K Units (2025-2030)
  • Table 521. Pain Management Therapeutics Sales Antidepressants , by Region K Units (2025-2030)
  • Table 522. Pain Management Therapeutics Sales Anti-migraine agents , by Region K Units (2025-2030)
  • Table 523. Pain Management Therapeutics Sales Non-narcotic analgesics , by Region K Units (2025-2030)
  • Table 524. Pain Management Therapeutics Sales Opioids , by Region K Units (2025-2030)
  • Table 525. Pain Management Therapeutics Sales: by Distribution channel(K Units)
  • Table 526. Pain Management Therapeutics Sales Hospitals Pharmacy , by Region K Units (2025-2030)
  • Table 527. Pain Management Therapeutics Sales Retail Pharmacy , by Region K Units (2025-2030)
  • Table 528. Pain Management Therapeutics Sales Online Pharmacy , by Region K Units (2025-2030)
  • Table 529. South America Pain Management Therapeutics Sales, by Country K Units (2025-2030)
  • Table 530. South America Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 531. South America Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 532. South America Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 533. South America Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 534. South America Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 535. Brazil Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 536. Brazil Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 537. Brazil Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 538. Brazil Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 539. Brazil Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 540. Argentina Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 541. Argentina Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 542. Argentina Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 543. Argentina Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 544. Argentina Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 545. Rest of South America Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 546. Rest of South America Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 547. Rest of South America Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 548. Rest of South America Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 549. Rest of South America Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 550. Asia Pacific Pain Management Therapeutics Sales, by Country K Units (2025-2030)
  • Table 551. Asia Pacific Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 552. Asia Pacific Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 553. Asia Pacific Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 554. Asia Pacific Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 555. Asia Pacific Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 556. China Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 557. China Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 558. China Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 559. China Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 560. China Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 561. Japan Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 562. Japan Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 563. Japan Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 564. Japan Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 565. Japan Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 566. India Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 567. India Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 568. India Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 569. India Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 570. India Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 571. South Korea Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 572. South Korea Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 573. South Korea Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 574. South Korea Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 575. South Korea Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 576. Taiwan Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 577. Taiwan Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 578. Taiwan Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 579. Taiwan Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 580. Taiwan Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 581. Australia Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 582. Australia Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 583. Australia Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 584. Australia Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 585. Australia Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 586. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 587. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 588. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 589. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 590. Rest of Asia-Pacific Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 591. Europe Pain Management Therapeutics Sales, by Country K Units (2025-2030)
  • Table 592. Europe Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 593. Europe Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 594. Europe Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 595. Europe Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 596. Europe Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 597. Germany Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 598. Germany Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 599. Germany Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 600. Germany Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 601. Germany Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 602. France Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 603. France Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 604. France Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 605. France Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 606. France Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 607. Italy Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 608. Italy Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 609. Italy Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 610. Italy Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 611. Italy Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 612. United Kingdom Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 613. United Kingdom Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 614. United Kingdom Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 615. United Kingdom Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 616. United Kingdom Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 617. Netherlands Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 618. Netherlands Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 619. Netherlands Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 620. Netherlands Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 621. Netherlands Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 622. Rest of Europe Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 623. Rest of Europe Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 624. Rest of Europe Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 625. Rest of Europe Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 626. Rest of Europe Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 627. MEA Pain Management Therapeutics Sales, by Country K Units (2025-2030)
  • Table 628. MEA Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 629. MEA Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 630. MEA Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 631. MEA Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 632. MEA Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 633. Middle East Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 634. Middle East Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 635. Middle East Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 636. Middle East Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 637. Middle East Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 638. Africa Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 639. Africa Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 640. Africa Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 641. Africa Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 642. Africa Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 643. North America Pain Management Therapeutics Sales, by Country K Units (2025-2030)
  • Table 644. North America Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 645. North America Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 646. North America Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 647. North America Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 648. North America Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 649. United States Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 650. United States Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 651. United States Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 652. United States Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 653. United States Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 654. Canada Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 655. Canada Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 656. Canada Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 657. Canada Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 658. Canada Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 659. Mexico Pain Management Therapeutics Sales, by Type K Units (2025-2030)
  • Table 660. Mexico Pain Management Therapeutics Sales, by Application K Units (2025-2030)
  • Table 661. Mexico Pain Management Therapeutics Sales, by Indication K Units (2025-2030)
  • Table 662. Mexico Pain Management Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 663. Mexico Pain Management Therapeutics Sales, by Distribution channel K Units (2025-2030)
  • Table 664. Pain Management Therapeutics: by Type(USD/Units)
  • Table 665. Research Programs/Design for This Report
  • Table 666. Key Data Information from Secondary Sources
  • Table 667. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Europe Pain Management Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Europe Pain Management Therapeutics: by Application USD Million (2018-2023)
  • Figure 6. Europe Pain Management Therapeutics: by Drug Class USD Million (2018-2023)
  • Figure 7. Europe Pain Management Therapeutics: by Distribution channel USD Million (2018-2023)
  • Figure 8. South America Pain Management Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Pain Management Therapeutics Share (%), by Country
  • Figure 10. Europe Pain Management Therapeutics Share (%), by Country
  • Figure 11. MEA Pain Management Therapeutics Share (%), by Country
  • Figure 12. North America Pain Management Therapeutics Share (%), by Country
  • Figure 13. Europe Pain Management Therapeutics: by Type K Units (2018-2023)
  • Figure 14. Europe Pain Management Therapeutics: by Application K Units (2018-2023)
  • Figure 15. Europe Pain Management Therapeutics: by Drug Class K Units (2018-2023)
  • Figure 16. Europe Pain Management Therapeutics: by Distribution channel K Units (2018-2023)
  • Figure 17. South America Pain Management Therapeutics Share (%), by Country
  • Figure 18. Asia Pacific Pain Management Therapeutics Share (%), by Country
  • Figure 19. Europe Pain Management Therapeutics Share (%), by Country
  • Figure 20. MEA Pain Management Therapeutics Share (%), by Country
  • Figure 21. North America Pain Management Therapeutics Share (%), by Country
  • Figure 22. Europe Pain Management Therapeutics: by Type USD/Units (2018-2023)
  • Figure 23. Europe Pain Management Therapeutics share by Players 2023 (%)
  • Figure 24. Europe Pain Management Therapeutics share by Players (Top 3) 2023(%)
  • Figure 25. Europe Pain Management Therapeutics share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Endo International Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Endo International Plc. (Ireland) Revenue: by Geography 2023
  • Figure 31. Depomed, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Depomed, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Purdue Pharma L.P. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Purdue Pharma L.P. (United States) Revenue: by Geography 2023
  • Figure 35. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 36. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 37. Mallinckrodt Pharmaceuticals (UK) Revenue, Net Income and Gross profit
  • Figure 38. Mallinckrodt Pharmaceuticals (UK) Revenue: by Geography 2023
  • Figure 39. AstraZeneca PLC. (UK) Revenue, Net Income and Gross profit
  • Figure 40. AstraZeneca PLC. (UK) Revenue: by Geography 2023
  • Figure 41. Novartis AG(Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis AG(Switzerland) Revenue: by Geography 2023
  • Figure 43. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 47. Europe Pain Management Therapeutics: by Type USD Million (2025-2030)
  • Figure 48. Europe Pain Management Therapeutics: by Application USD Million (2025-2030)
  • Figure 49. Europe Pain Management Therapeutics: by Drug Class USD Million (2025-2030)
  • Figure 50. Europe Pain Management Therapeutics: by Distribution channel USD Million (2025-2030)
  • Figure 51. South America Pain Management Therapeutics Share (%), by Country
  • Figure 52. Asia Pacific Pain Management Therapeutics Share (%), by Country
  • Figure 53. Europe Pain Management Therapeutics Share (%), by Country
  • Figure 54. MEA Pain Management Therapeutics Share (%), by Country
  • Figure 55. North America Pain Management Therapeutics Share (%), by Country
  • Figure 56. Europe Pain Management Therapeutics: by Type K Units (2025-2030)
  • Figure 57. Europe Pain Management Therapeutics: by Application K Units (2025-2030)
  • Figure 58. Europe Pain Management Therapeutics: by Drug Class K Units (2025-2030)
  • Figure 59. Europe Pain Management Therapeutics: by Distribution channel K Units (2025-2030)
  • Figure 60. South America Pain Management Therapeutics Share (%), by Country
  • Figure 61. Asia Pacific Pain Management Therapeutics Share (%), by Country
  • Figure 62. Europe Pain Management Therapeutics Share (%), by Country
  • Figure 63. MEA Pain Management Therapeutics Share (%), by Country
  • Figure 64. North America Pain Management Therapeutics Share (%), by Country
  • Figure 65. Europe Pain Management Therapeutics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Endo International Plc. (Ireland)
  • Depomed, Inc. (United States)
  • Purdue Pharma L.P. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Mallinckrodt Pharmaceuticals (UK)
  • AstraZeneca PLC. (UK)
  • Novartis AG(Switzerland)
  • Merck & Co. Inc. (United States)
  • Johnson & Johnson Services, Inc. (United States)
Additional players considered in the study are as follows:
GlaxoSmithKline Plc (UK) , Abbott Laboratories (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 217 Pages 97 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pain Management Therapeutics Market Quantitative research analysis
Global Pain Management Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Pain Management Therapeutics study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Pain Management Therapeutics Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Europe Pain Management Therapeutics market is expected to see growth rate of xx%.
The Pain Management Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Pain Management Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Mobile Clinics Comprehensive Study by Type (Eye-wear, Mobile health, Connected medical devices, Mhealth apps), Application (Diabetes, Cardiovascular Disease, Respiratory Diseases, Neurological Diseas...
$ 3500
Dental Wax Comprehensive Study by Type (Mineral Wax, Animal Wax, Plant Wax, Synthetic Wax), Application (Hospitals, Dentist Clinics, Academic and Research Centers, Others) Players and Region - Global...
$ 3500
Marijuana Oil Comprehensive Study by Type (Organic, Inorganic), Application (Vape Cartirdges, Subligual Drops& Sprays, Topical Creams & Salves, Gummies & Edibles, Softgel Capsules, Others), End Use (...
$ 3450
IT-enabled Healthcare Comprehensive Study by Application (Hospitals , Clinics , Household , Others), Services (M-Health, Tele-health Services), Software (Ancillary Information Systems, Administrative...
$ 3450
Extraction Devices Comprehensive Study by Type (Solid Phase, Liquid Phase), End User (Healthcare Industries, Chemical Industries, Food Industries, Others) Players and Region - Global Market Outlook t...
$ 3500
Red Cell Filter Comprehensive Study by Type (Whole blood transfusion, Platelet transfusion, Red cell transfusion), Application (Blood bank blood bags, Besides blood transfusion) Players and Region - ...
$ 3500